Company · Biotech and pharma · 3D printing
3D bioprinted cell models for reproducible drug discovery
Sydney, NSW
Every investor coverage indicates participated in a round Inventia Life Sciences raised.
Investors whose own portfolio pages list Inventia Life Sciences, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Blackbird Ventures | its portfolio page ↗ |
| KP Rx | its portfolio page ↗ |
Companies Inventia Life Sciences acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Aidan O'Mahony | Co-founder and Chief Technology Officer | Blackbird Ventures portfolio, Inventia Life Sciences team page |
| Dr Cameron Ferris | Co-founder and Chief Executive Officer | Blackbird Ventures portfolio, Inventia Life Sciences team page |
Stories naming Inventia Life Sciences. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Wholesale Investor's Steve Torso highlights Australian life sciences companies from the Emergence Preview Series, noting government grant funding, a Series A extension, venture co-investment, and a medtech company's ASX listing.
Also Wholesale Investor
Blackbird interviews Remedy Robotics co-founder Dave Bell about his move from medicine to surgical robotics and his mentoring in its Foundry program, noting Foundry applications are open.
Blackbird's founder profile interviews Inventia Life Sciences' CEO about his career, co-founders and the RASTRUM 3D bioprinting platform, recalling the firm's early investment in the Sydney biotech company.
An AirTree partner argues Australia's healthtech sector must champion centralised health data, citing local AI diagnostics and bioprinting startups and claiming MyHealthRecord's aggregated data could enable life-saving medical insights.